[Informe de investigación] El CIN & Se espera que el tamaño del mercado de tratamiento del VPH-AR alcance los 17.164,61 millones de dólares en 2028 desde los 11.635,17 millones de dólares en 2022; Se estima que el mercado registrará una CAGR del 6,7 % entre 2023 y 2028.
El CIN & El mercado de tratamiento del VPH-AR está segmentado según el tipo de enfermedad, el tipo de cepa, la oferta, el tipo de producto, el usuario final y la geografía. El informe ofrece información y un análisis en profundidad del mercado, enfatizando parámetros como impulsores, tendencias y oportunidades en el mercado y un análisis del panorama competitivo de los principales actores del mercado en varias regiones. También incluye análisis del impacto de la pandemia de COVID-19 en las principales regiones.
Perspectivas del mercado
Iniciativas favorables para la prevención del cáncer de cuello uterino impulsan la NIC y la prevención del cáncer de cuello uterino. Crecimiento del mercado de tratamiento del VPH-AR
En agosto de 2020, la Organización Mundial de la Salud (OMS) ideó una estrategia global para la eliminación del cáncer de cuello uterino. Según esta estrategia, todos los países del mundo deben centrarse en alcanzar y mantener una tasa de incidencia inferior a 4 por 100.000 mujeres para eliminar el cáncer de cuello uterino. Para lograr tasas de incidencia tan bajas, los países deben centrarse en la detección, el tratamiento y la vacunación del cáncer de cuello uterino. Medicare, un popular programa de seguro gubernamental, brinda cobertura para pruebas de Papanicolaou, exámenes pélvicos y exámenes clínicos de mama realizados cada dos años para la detección del cáncer de cuello uterino.
Unitaid, una agencia de salud global que trabaja para generar soluciones innovadoras para prevenir, diagnosticar y tratar enfermedades importantes en países de ingresos bajos y medios, ha presentado una nueva iniciativa para la prevención del cáncer de cuello uterino. Sus esfuerzos se centran en ampliar el acceso a herramientas y servicios críticos para detectar los primeros signos de cáncer de cuello uterino, seguidos del tratamiento de los casos positivos. Unitaid brinda apoyo a la Iniciativa Clinton de Acceso a la Salud (CHAI) y al Proyecto Ampliar la Eliminación del Cáncer Cervical con una Estrategia de Prevención Secundaria (SUCCESS), que se llevan a cabo en asociación con Expertise France, Jhpiego y la Unión para el Control Internacional del Cáncer ( UICC). Unitaid está colaborando con estos socios y gobiernos de 14 países de ingresos bajos y medios para desarrollar un paquete de herramientas asequible y altamente eficaz, que puede ayudar a la Organización Mundial de la Salud a alcanzar sus objetivos de eliminación del cáncer de cuello uterino. Unitaid ha invertido ~70 millones de dólares en herramientas innovadoras para detectar enfermedades precancerosas en mujeres que viven en entornos de bajos recursos y tratarlas. En 14 países, Unitaid se esfuerza por superar las barreras de acceso y sentar las bases para los esfuerzos nacionales de eliminación del cáncer de cuello uterino, demostrando modelos efectivos de prevención en países de ingresos bajos y medianos.
Perspectivas estratégicas
< p>En la India, los métodos de detección como la citología, las pruebas conjuntas (VPH + citología), las pruebas primarias de VPH y la inspección visual con ácido acético se emplean en diversos entornos, de acuerdo con la disponibilidad de recursos y los estándares de cumplimiento. La Federación de Obstetras y Ginecólogos de la India (FOGSI) ha publicado recomendaciones de buenas prácticas clínicas (GCPR) para el tratamiento de mujeres con resultados positivos en diferentes entornos de recursos. RMNCH + A (que significa Salud Reproductiva Materna Neonatal Infantil + Salud del Adolescente + Adolescente) es la estrategia de la Misión Nacional de Salud de la India (NHM) que fomenta normas familiares reducidas. Esta estrategia implica la entrega de anticonceptivos a domicilio por parte de activistas de salud social acreditados (ASHA), retrasar la edad para contraer matrimonio, promover la higiene menstrual y la conciencia sobre la higiene sexual e impulsar el tratamiento de enfermedades del tracto reproductivo en "Clínicas Suraksha".Tales Las iniciativas de varias organizaciones sanitarias y gobiernos para prevenir el cáncer de cuello uterino impulsan el crecimiento de CIN & Mercado de tratamiento del VPH-AR.
Información basada en el tipo de enfermedad
Según el tipo de enfermedad, el CIN & El mercado de tratamiento del VPH-AR está segmentado en neoplasia intraepitelial cervical 1 (NIC 1), neoplasia intraepitelial cervical 2 (NIC 2) y neoplasia intraepitelial cervical 3 (NIC 3). En 2022, el segmento de neoplasia intraepitelial cervical 3 (CIN 3) tuvo la mayor participación de mercado y se prevé que registre la CAGR más alta durante el período de pronóstico.
CIN & Mercado de tratamiento del VPH-AR, por tipo de enfermedad: 2022-2028
Información basada en el tipo de cepa
Según el tipo de cepa, el CIN & El mercado de tratamiento del VPH-AR está segmentado en VPH 16, VPH 18 y otros. El segmento HPV 16 tuvo la mayor participación de mercado en 2022. Se espera que el segmento HPV 18 registre la CAGR más alta durante el período de pronóstico.
Información basada en ofertas
Basado en oferta, el CIN & El mercado de tratamiento del VPH-AR se clasifica en método de diagnóstico y tratamiento. En 2022, el segmento de tratamiento tenía una mayor cuota de mercado. Sin embargo, se espera que el segmento de métodos de diagnóstico registre una CAGR más alta durante el período de pronóstico. Además, el segmento de métodos de diagnóstico se clasifica en pruebas de VPH, prueba de Papanicolaou, colposcopia y biopsia. El segmento de pruebas del VPH tuvo la mayor participación en el mercado de métodos de diagnóstico en 2022. Además, el segmento de tratamiento se divide en cirugía de escisión y técnicas de ablación. En 2022, el segmento de técnicas ablativas tuvo una mayor participación de mercado y se prevé que registre una CAGR más alta en el mercado durante el período de pronóstico.
Información basada en el tipo de producto
Basada según el tipo de producto, el CIN & El mercado de tratamiento del VPH-AR se segmenta en kits y tratamientos. reactivos, instrumentos y servicios. El segmento de servicios tuvo la mayor participación del mercado en 2022 y se espera que registre la CAGR más alta durante el período de pronóstico.
Información basada en el usuario final
Basada en el usuario final , el CIN & El mercado de tratamiento del VPH-AR está segmentado en hospitales y hospitales. clínicas, laboratorios de diagnóstico, laboratorios clínicos especializados, y otros. El hospital & El segmento de clínicas representó la mayor participación de mercado en 2022. Se espera que el segmento de laboratorios de diagnóstico registre la CAGR más alta durante el período de pronóstico.
El CIN & Los actores del mercado de Tratamiento del VPH-AR adoptan estrategias orgánicas, como el lanzamiento y la expansión de productos, para ampliar su huella geográfica y sus carteras de productos. Además, estas estrategias de crecimiento ayudan a las empresas a fortalecer su clientela y ampliar sus carteras de productos.
- En octubre de 2022, Fujirebio Europe y Self-screen BV formaron una colaboración comercial. para distribuir el ensayo de diagnóstico in vitro molecular (IVD) específico de metilación PreCursor-M+ (una marca registrada de Self-screen BV). La prueba está destinada a detectar cualitativamente los niveles elevados de metilación de los biomarcadores del cáncer de cuello uterino. Puede utilizarse como prueba de seguimiento de clasificación en mujeres con resultados positivos para el VPH y citología ASCUS/LSIL. El ensayo PreCursor-M+ completa la cartera de pruebas moleculares específicas del VPH de Fujirebio.
- En abril de 2021, Roche recibió la aprobación de la FDA de EE. UU. para los sistemas cobas 6800/8800 de alto rendimiento y totalmente automatizados para su uso en las pruebas del VPH. La prueba cobas HPV identifica a las mujeres con riesgo de cáncer de cuello uterino al detectar la presencia de ADN del hrHPV en muestras de cuello uterino. cobas HPV está indicado para la detección rutinaria del cáncer de cuello uterino según las pautas médicas profesionales, incluida la clasificación de citología ASC-US y la detección primaria del VPH en mujeres para evaluar el riesgo de cáncer y precáncer de cuello uterino.
Perfiles de la empresa
- Fujirebio Europa NV
- Qiagen NV
- Zilico Ltd
- Laboratorios Abbott
- Cefeida ;
- F. Hoffmann-La Roche Ltd
- INOVIO Pharmaceuticals Inc
- Bioneer Corp
- Antiva Biosciences Inc
- Thermo Fisher Scientific Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global CIN and HR-HPV Treatment Market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the CIN and HR-HPV Treatment Market in 2021. With several North American market players focusing on research and development activities, the regional market for CIN and HR-HPV Treatment Market is likely to propel in North America region during the forecast period.
Abbott and Cepheid are the top two companies that hold huge market shares in the CIN & HR-HPV Treatment Market.
The CIN and HR-HPV Treatment Market majorly consists of the players such Fujirebio Europe NV, Qiagen NV, Zilico Ltd, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, INOVIO Pharmaceuticals Inc, Bioneer Corp, Antiva Biosciences Inc, and Thermo Fisher Scientific Inc.
The hospitals & clinics segment dominated the global CIN and HR-HPV Treatment Market and held the largest market share in 2021.
The CAGR value of the CIN and HR-HPV Treatment Market during the forecasted period of 2022-2028 is 6.7%.
Cervical Intraepithelial Neoplasia 3 segment held the largest share of the market in the global CIN and HR-HPV Treatment Market and held the largest market share of 47.48% in 2022.
High-risk HPV is associated with cervical intraepithelial neoplasia (CIN). Persistent infection with high-risk human papillomavirus (HPV) results in invasive cervical cancer. Also, HR-HPV subtypes particularly HPV 16 and HPV 18 causes cervical cancer. The main aim of NHS Cervical Screening Program (NHS CSP) is to reduce the incidence and mortality from cervical cancer through a systematic, quality-assured population-based screening program for people aged 24 to 64.
Key factors that are driving the growth of this market are Increase in prevalence of human papillomavirus infections and favorable Initiatives for preventing cervical cancer.
The List of Companies - CIN & HR-HPV Treatment Market
- Fujirebio Europe NV
- Qiagen NV
- Zilico Ltd
- Abbott Laboratories
- Cepheid
- F. Hoffmann-La Roche Ltd
- INOVIO Pharmaceuticals Inc
- Bioneer Corp
- Antiva Biosciences Inc
- Thermo Fisher Scientific Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
May 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
May 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
May 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
May 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
May 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)